The Gender Skin Gap

This International Women’s Day, we are spotlighting the data, because when it comes to skincare science, representation should extend far beyond imagery and into the laboratory itself.

Female skin is biologically dynamic, continually evolving in response to hormonal rhythms, life stages, stress exposure and immune activity, and yet clinical testing environments have historically treated it as static, simplified and interchangeable.

The result is what we call the gender skin gap — not a gap in marketing language, but a gap in research design.

Collagen Loss & The Menopausal Shift

In the first five years of menopause, women can lose up to 30% of their collagen, a structural protein essential for firmness, elasticity and resilience, resulting in visible and measurable changes to skin thickness, hydration and tensile strength.

This is not gradual ageing unfolding predictably over decades; it is a profound biological shift driven by declining oestrogen levels that directly influence dermal density and barrier integrity.

Perimenopause, the transitional stage that precedes menopause, accelerates this structural change, yet few cosmetic clinical trials isolate it as a distinct physiological phase, despite the fact that it is often during these years that women first experience sudden dryness, increased sensitivity, and loss of elasticity.

These transformative stages are frequently grouped into broad age categories or omitted entirely, leaving a significant gap between lived experience and laboratory data.

Female skin is biologically dynamic and clinical testing should reflect that reality.

Adult Acne & Hormonal Inflammation

Up to 40% of adult women experience acne, yet unlike adolescent acne, which is often linked primarily to excess sebum production during puberty, adult acne tends to be hormonal, inflammatory and cyclical, commonly presenting along the jawline and lower face.

It is frequently intertwined with stress responses, fluctuations in progesterone and oestrogen, and underlying barrier fragility, making it a distinctly different biological presentation from teenage breakouts.

And yet treatment protocols and clinical trials have historically centred around adolescent cohorts, leaving adult women navigating conditions that are hormonally complex but scientifically underrepresented.

Adult female acne is not an extension of teenage skin; it is a separate clinical category requiring nuanced research, barrier-conscious formulations and testing conditions that account for hormonal variability.

Autoimmune Conditions, Stress & Barrier Fragility

Women are three to four times more likely to develop autoimmune conditions, many of which manifest visibly through chronic inflammation, heightened sensitivity and compromised barrier function.

Inflammation and barrier fragility are not niche concerns; they are central to understanding female skin physiology, particularly when immune dysregulation and hormonal shifts intersect.

Compounding this is the biological impact of stress. Elevated cortisol levels reduce collagen production, impair barrier repair and increase water loss, slowing recovery and amplifying visible signs of fatigue and irritation.

Chronic stress, which disproportionately affects women balancing professional, familial and emotional labour, has measurable dermatological consequences — yet stress exposure is rarely factored into cosmetic clinical testing environments that prioritise controlled variables over real-life context.

Female skin does not exist in isolation from endocrine fluctuation, sleep disruption or immune activity, so therefore science must account for this complexity.

Postpartum & Under-Researched Transitions

Postpartum hormonal shifts can trigger pigmentation, acne, dryness and profound changes in skin sensitivity, as the body recalibrates from pregnancy-level hormone concentrations back to baseline.

These months, marked by significant endocrine and emotional change, represent one of the most biologically transformative periods in a woman’s life — and yet they are often excluded from clinical trials.

Similarly, perimenopause accelerates structural decline, menopause reshapes dermal architecture, and chronic stress alters inflammatory signalling pathways, but these hormonally dynamic phases remain under-isolated in research models.

Female skin does not age in a straight line. It evolves monthly, cyclically and hormonally.

Closing the Gap

At OSKIA, we believe that skincare should be grounded in biological truth rather than demographic assumption.

Our clinical trials are designed to reflect hormonally dynamic, real-life female skin, accounting for fluctuation, inflammation, barrier sensitivity and structural change, because women’s skin deserves to be studied with the same nuance with which it is marketed.

This International Women’s Day, we are not simply celebrating women; we are advocating for research that genuinely represents them.